PET/CT and MRI in Evaluating Cervical Cancer
- Authors
-
-
Runjun Shi
Department of Radiotherapy, Suzhou Affiliated Hospital of Nanjing Medical University, Suzhou, 215000, China -
Jie Chen
Department of Radiotherapy, Suzhou Affiliated Hospital of Nanjing Medical University, Suzhou, 215000, China -
Jinchang Wu
Department of Radiotherapy, Suzhou Affiliated Hospital of Nanjing Medical University, Suzhou, 215000, China -
Jundong Zhou
Department of Radiotherapy, Suzhou Affiliated Hospital of Nanjing Medical University, Suzhou, 215000, China
-
- Keywords:
- Positron emission tomography, magnetic resonance,cervical cancer, staging, treatment response, recurrence.
- Abstract
-
Positron emission tomography (PET)/computed tomography (CT) and magnetic resonance (MR) imaging are two most important imaging tools for evaluating cervical cancer in clinic. They have improved the accuracy of tumor staging and prognosis predicting in a large part. PET/CT is superior for lymph node (LN) status and metastasis to other imaging modalities. And it could differ among tumor types and grades according to maximum standardized uptake value (SUVmax). MRI is not sensitive to LN metastasis, but it shares the advantage of therapeutic response and recurrence evaluation with PET/CT. Recently, emerging functional imaging modality Diffusion-weighted imaging (DWI) has been showing its superiority on evaluation of cervical carcinoma as well. This article describes both advantages and limitations of MR imaging and PET/CT in evaluating cervical cancer, and reviews the current role of imaging techniques mentioned above.
- Downloads
-
Download data is not yet available.
- Downloads
- Published
- 14-01-2016
- Issue
- Vol. 5 No. 1 (2016)
- Section
- Articles
How to Cite
Similar Articles
- S.K. Gantsev , S.R. Kzyrgalin, K.S. Gantsev, Peritumoral Lymphangiogenesis in Breast Carcinoma , Journal of Cancer Research Updates: Vol. 9 No. 1 (2020)
- Yao Li, Meng-Ning Wei, Wen-Ji Zhang, Zhi Shi, A HPLC-UV Method for the Quantification of Regorafenib in Tumor , Journal of Cancer Research Updates: Vol. 9 No. 1 (2020)
- Ananda M. Chakrabarty, COMMENTARY: BRCA1/2 Mutations, Vulnerability to Breast/Ovarian Cancer, and Current and Future Treatment Modalities , Journal of Cancer Research Updates: Vol. 5 No. 2 (2016)
- Tibor Hajto, Angelika Kirsch, Case Reports of Cancer Patients with Hepatic Metastases Treated by Standardized Plant Immunomodulatory Preparations , Journal of Cancer Research Updates: Vol. 2 No. 1 (2013)
- Dan-Ping Huang, Yi-Jun Chen, Jie-Si Luo, Shao-Qian Chen, Jing Cheng, Yu Li, Cong Liang, Li-Na Wang, Zhong Fan, Xiao-Li Zhang, Xue-Qun Luo, Li-Bin Huang, Yan-Lai Tang, PCR- Negative Atypical PML-RARA Rearrangement in Pediatric Acute Promyelocytic Leukemia , Journal of Cancer Research Updates: Vol. 10 (2021)
- Sana Belkahla, Dichloroacetate Reprograms JunD Expression and Enhances Chemosensitivity in Acute Myeloid Leukemia via p53 Status , Journal of Cancer Research Updates: Vol. 15 No. 2 (2026)
- Irene Ruiz, Freddy Fernando Durán, Carmen Sáez, Julián Sanz, Adela Pelayo, Fernando Moreno, Jorge Ruiz, Luis Ortega, Alejandro Pascual, HER2 Expression Discordance between Ductal Carcinoma In situ and Invasive Breast Carcinoma. How to Analyze Oncotype DX , Journal of Cancer Research Updates: Vol. 8 No. 1 (2019)
- Hassan Bahrami, Majid Tafrihi, Understanding the Warburg Effect Yields New Insights into the Metabolic Control of Cancer , Journal of Cancer Research Updates: Vol. 12 (2023)
- Joseph V. Pergolizzi Jr., Robert B. Raffa, Emilio Esteban Gonzalez, Jo Ann LeQuang, A Guide for Cancer Pain Management in Latin America , Journal of Cancer Research Updates: Vol. 6 No. 4 (2017)
- Kenji Ina, Yuko Kato, Kengo Nanya, Satoshi Hibi, Yuko Shirokawa, Tomoko Toda, Satoshi Kayukawa, Adaptation to the Progress in Cancer Genomic Medicine by a Japanese Community Hospital , Journal of Cancer Research Updates: Vol. 12 (2023)
You may also start an advanced similarity search for this article.